Enfortumab vedotin with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer

Enfortumab vedotin in combination with pembrolizumab is in clinical development for the treatment
of patients with previously untreated locally advanced or metastatic urothelial cancer (UC). UC occurs
on the lining of the renal pelvis, ureter, bladder and urethra, and other parts of the urinary system.
Metastatic UC occurs when the cancer has spread to other parts of the body. Durable responses are
rare with current standard of care treatments. Therefore, treatment approaches with longer-term
disease control and extending to broader metastatic UC patient populations are needed.